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Abstract
Background: Prognostic models are typically developed in studies covering long time
periods. However, if more recent years have seen improvements in survival, then using
the full dataset may lead to out-of-date survival predictions. Period analysis addresses
this by developing the model in a subset of the data from a recent time window, but
results in a reduction of sample size.
Methods: We propose a new approach, called temporal recalibration, to combine the
advantages of period analysis and full cohort analysis. This approach develops a model
in the entire dataset and then recalibrates the baseline survival using a period analysis
sample.
The approaches are demonstrated utilizing a prognostic model in colon cancer built us-
ing both Cox proportional hazards and flexible parametric survival models with data
from 1996–2005 from the Surveillance, Epidemiology, and End Results (SEER) Program
database. Comparison of model predictions with observed survival estimates were
made for new patients subsequently diagnosed in 2006 and followed-up until 2015.
Results: Period analysis and temporal recalibration provided more up-to-date survival
predictions that more closely matched observed survival in subsequent data than the
standard full cohort models. In addition, temporal recalibration provided more precise
estimates of predictor effects.
Conclusion: Prognostic models are typically developed using a full cohort analysis that
can result in out-of-date long-term survival estimates when survival has improved in re-
cent years. Temporal recalibration is a simple method to address this, which can be used
when developing and updating prognostic models to ensure survival predictions are
more closely calibrated with the observed survival of individuals diagnosed
subsequently.
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Introduction
For individuals diagnosed with a particular disease or
health condition, prognostic models can provide outcome
predictions and aid treatment decisions.1,2 In this article,
we focus on the outcome of time-until-death from colon
cancer and survival predictions, however the approach can
be generalized. Prognostic models contain multiple predic-
tors and are typically developed using a regression format
such as logistic, Cox or a parametric survival model. It is
often of interest to provide survival predictions at different
time points, such as 1, 5 and 10 years after diagnosis. For
10-year predictions, it is necessary to have a model devel-
opment dataset that includes individuals who were diag-
nosed at least 10 years ago, such that the analysis has
sufficient follow-up length. However, this can lead to out-
of-date (miscalibrated) survival predictions for recently di-
agnosed individuals if there have been improvements in
survival over calendar time: e.g. in recent years treatment
may have improved survival compared with 5 or 10 years
earlier. Improvements in survival for colorectal cancer
have been reported in a number of different countries.3–6
With the development of online tools and apps, survival
estimates from prognostic models have become more ac-
cessible. Some models such as PREDICT, a prognostic
model for breast cancer,7 and QCancer, a prognostic
model for colorectal cancer,8 are freely available online for
both clinicians and the public. The survival estimates pro-
duced from these, and many other webtools, are from a
standard full cohort analysis approach. Such models may
produce survival predictions that under-estimate the true
survival probability of recently diagnosed patients (and
conversely over-estimate the actual risk of adverse
outcomes).
Period analysis has been used in population-based can-
cer studies to obtain up-to-date estimates of survival9–12
and in this article we explore its use in the development
and updating of prognostic models. Period analysis defines
a recent time window and only the risk-time and events
that fall within this window contribute to the estimates of
the hazard rates and predictor effects.13 This method is not
commonly used for prognostic models, however Keogh
et al.14 produced survival predictions for cystic fibrosis
patients using period analysis. A disadvantage with period
analysis is that it results in a reduction of sample size for
model development. This could be particularly problem-
atic in small datasets, when there are rare predictor pat-
terns or rare events, and may lead to a low number of
events per predictor parameter, which increases the poten-
tial for model overfitting.15
In this article we introduce a new approach, called tempo-
ral recalibration, that combines the use of full cohort analy-
sis, period analysis and recalibration methods. Specifically it
aims to maximize the use of data toward model develop-
ment, with the full dataset used to model predictor effects
and the baseline survival recalibrated in a recent time win-
dow to produce more up-to-date survival predictions for
new individuals. We illustrate and compare these methods
using an example of colon cancer from the Surveillance,
Epidemiology, and End Results (SEER) Program database.16
Methods
Cox proportional hazards models and post-
estimation of the baseline
Cox proportional hazards (PH) models are frequently used
to develop prognostic models.17 The model is of the form:
Key Messages
• If survival has been improving over time, standard full cohort models can under-estimate survival.
• Period analysis uses a more recent subset of data to produce survival estimates which are more up-to-date, however
it reduces the sample size and number of events used in the analysis.
• Temporal recalibration combines the sample size advantages associated with full cohort analysis with the up-to-date
estimates produced with period analysis.
• Temporal recalibration can be used at the model development stage or to update existing prognostic models when
new data becomes available.
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hðt;xiÞ ¼ h0ðtÞebxi
with hðt;xiÞ the hazard function, h0ðtÞ the baseline hazard
function and bxi the prognostic index.
18
The cumulative hazard function Hðt;xiÞ must be approxi-
mated to calculate survival predictions as it is not directly
modelled. This can be achieved post-estimation using a non-
parametric approach, or by a smoother using fractional poly-
nomials or splines.7,19 In this article, restricted cubic splines
are used to create a smooth approximation of the log cumula-
tive baseline hazard post-estimation. The same knot locations
as the flexible parametric survival models (FPMs) (see
Supplementary File 1, available as Supplementary data at IJE
online) were used to ensure a fair comparison. The baseline
survival curve was approximated by S^0 tð Þ ¼ eH^0 ðtÞ, and sur-
vival predictions for individuals with different values of the
prognostic index by S^ t; xið Þ ¼ S^0ðtÞe
b^xi
.
It is possible to extend these models to include time-
dependent predictor effects (i.e. non-proportional haz-
ards). Period analysis20 (see the Period analysis section)
can be performed using delayed entry techniques.
Flexible parametric survival models
Although Cox models are widely used for prognostic
modelling, FPMs have several advantages. FPMs directly
model the log baseline cumulative hazard function which
allows for smooth survival curves to be produced during
model development, without the need for post-estimation
smoothing.21 It remains straightforward to include time-
dependent predictor effects22 and incorporate delayed en-
try. FPMs use restricted cubic splines to directly model
the baseline ln H0 t; xið Þ
 
(see Supplementary File 1, avail-
able as Supplementary data at IJE online). A prognostic
model can be written in the following form where
f ln tð Þjc; k0Þ

is the restricted cubic spline function and bxi
is the prognostic index.23
ln Hðt; xiÞ½  ¼ f ln tð Þjc; k0Þ þ bxi

Period analysis
Period analysis, in the context of population-based cancer
data, was developed by Brenner and Gefeller.20 Only indi-
viduals who contribute follow-up time during the period
window are included in the analysis to estimate predictor
effects and baseline survival (see Table 1). This reduces the
sample size since people who experienced the event before
the window (e.g. Participant B, see Figure 1) are excluded.
Only the events that occur within the window are consid-
ered in the analysis and therefore the choice of window
width is a balance between ensuring up-to-date survival
estimates and having sufficient events (and events per pre-
dictor parameter). The width of the window could be de-
termined by meeting the criteria defined by Riley et al.15
Further details and a sensitivity analysis of using different
window widths are included in Supplementary File 4,
available as Supplementary data at IJE online.
Delayed entry techniques are used to left truncate the
follow-up time of people diagnosed before the window so
that the short-term hazard rates are only estimated from
those diagnosed within or shortly before the period win-
dow (e.g. Participant D, see Figure 1).
This method has been shown to produce more up-to-
date survival estimates than full cohort analysis in
population-based cancer settings for many types of cancer
in different countries9–12 and is used routinely within inter-
national cancer survival comparisons.3,24
Temporal recalibration
A key disadvantage with period analysis is the reduction in
sample size and number of events for model estimation. To
address this, we propose temporal recalibration, which
combines the sample size advantages associated with the
full cohort analysis with the up-to-date predictions from
period analysis.
Figure 1 Contribution of follow-up time from four hypothetical participants (diagnosed 1 January) to a 2-year period window of 2004–05.
Table 1. Summary of the data used for the estimation of the
baseline and predictor effects for each method
Method Baseline Predictor effects
Full cohort Full Full
Temporal recalibration Recent Full
Period analysis Recent Recent
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The process of fitting a temporal recalibration model is as
follows. (i) Fit a survival model using the full cohort dataset
to estimate the predictor effects using all individuals. (ii)
Recalibrate the model by re-estimating the baseline using the
subset of individuals from a period analysis sample, while
holding the predictor effect estimates from step (i) fixed.
Recalibrating the baseline in a recent period analysis
sample allows for improvements in survival to be captured
and leads to more up-to-date predictions. Under propor-
tional hazards the model can be written in the following
form for FPMs:
ln Hnewðt;xiÞ½  ¼ fnewðln tð Þjc; k0Þ þ offsetðPIiÞ
where fnew ln tð Þjc; k0Þ

is the updated spline function for
the log cumulative baseline hazard function estimated in
the recent period data, k0 are the knot locations from the
full cohort model and offsetðPIiÞ is the prognostic index es-
timated from the full cohort model as an offset term.
Fixing the predictor effects with constraints when fitting in
the period analysis sample would offer an equivalent
approach.
For a Cox PH model it can be written as:
hnewðt;xiÞ ¼ h0newðtÞeoffsetðPIiÞ
where hnewðt;xiÞ and h0new tð Þ are the hazard and baseline
hazard functions respectively, estimated on the recent time
window, and offsetðPIiÞ is the prognostic index estimated
from the full cohort model as an offset term.
As with period analysis, the choice of the window width
is a bias-variance trade-off (see Supplementary File 4,
available as Supplementary data at IJE online). The width
of the window could possibly be reduced compared with a
standard period analysis approach as it is only necessary to
have a sufficient number of events to estimate the baseline
(and not the predictor effects). In temporal recalibration
we explicitly assume the predictor effects are the same as
they were in the full cohort model (see Table 1).
Assessing the performance of predictions
Marginal survival (i.e. average across all individuals) can
be calculated both within-sample (i.e. in the same dataset
used to develop the model) and out-of-sample (i.e. in new
individuals) by calculating every individual’s predicted sur-
vival over time, and then averaging the survival curves:25
S^ tð Þ ¼ 1
N
Xn
i¼1 S^ t;xið Þ
Out-of-sample marginal survival predictions can be
compared with the observed survival (Kaplan–Meier
estimates) to determine the calibration of a model’s sur-
vival predictions for a new group of individuals.
Studying the marginal survival only assesses how well
the model performs on average (sometimes referred to as
calibration-in-the-large1,26), whereas calibration plots can
be used to determine the model’s performance in different
risk groups at particular time points. In this article the risk
groups were defined by dividing the prognostic index from
the full cohort models into 10 equally sized risk groups.
The E/O statistic quantifies calibration-in-the-large by
comparing predicted or expected (E) outcome risk to the
observed (O) risk through EO tð Þ ¼
1S exp ðtÞ
1SobsðtÞ . E is calculated
from the marginal survival prediction from the model
[Sexp(t)] and O is from the observed Kaplan–Meier curve
[Sobs(t)]. A value of 1 indicates agreement
1,27
Harrell’s c-index can be used to assess the concordance
of survival predictions from proportional hazards models.
A value of 1 indicates perfect concordance.28
We now compare full cohort, temporal recalibration
and period analysis approaches using an illustrative exam-
ple of colon cancer.
Example
Data
We used the public-access SEER database from the USA.16
The SEER program covers 34% of the US population
and collects population-based data on all reported cases of
cancer within the cancer registries included in the SEER
program.29 The analysis was restricted to adults who were
aged 18–99 years at the time of their diagnosis of colon
cancer (ICD10 codes C18.0–C18.9). If there were any
duplicates of the patient ID, only the first record was
retained. Patients with an unknown survival time
(recorded to the nearest month) or incomplete dates for
their diagnosis or death were also excluded. Data from
1996–2015 were available for this analysis. As the aim was
to identify which model gave better long-term survival pre-
dictions in new data, the data were split at 2005 for illus-
tration purposes. Data from 1996–2005 were used to
develop the models and a 2 year period window from 1
January 2004 to 31 December 2005 was used to fit the
temporal recalibration and period analysis models. The
data from 2006–15 were then used to validate the models.
Baseline characteristics for the development dataset can be
found in Table 2.
Models
Cause-specific Cox and FPMs were fitted, meaning that
deaths due to causes other than colon cancer were
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censored. Age at diagnosis, stage at diagnosis (localized, re-
gional, distant), grade of the tumour (I–IV), sex and race
(restricted to White and Black patients only) were included
as predictors. Age was modelled using restricted cubic
splines with three degrees of freedom, and stage, grade, sex
and race were modelled categorically. All predictors were
forced to be included (i.e. there was no variable selection).
For the FPMs, five degrees of freedom were used to model
the log baseline cumulative hazard and, to simplify the pro-
cess of recalibration, the baseline splines were not orthogo-
nalized. Example code used to fit these models is provided
in Supplementary File 2, available as Supplementary data
at IJE online. In this illustrative example, any participants
with missing predictor values were excluded in order to
more easily compare the approaches, though in practice
multiple imputation is usually preferable.
Age at diagnosis was winsorized30 to provide more sta-
bility in the extremes by adding an additional constraint
forcing the splines to be constant for the top and bottom
2% of the age distribution.31 In further analyses, the PH
assumption was relaxed using time-dependent predictor
effects for age and stage. To compare the model predic-
tions from these three approaches, the marginal predicted
survival for the 5601 patients diagnosed in 2006 was cal-
culated using each model and compared with the observed
Kaplan–Meier estimates. This was further assessed through
calibration plots at 10 years after diagnosis.
All analyses were performed using Stata Version 15.0.32
FPMs were fitted using the user-written package stpm233
and Harrell’s c-index was calculated for these models using
the user-written package stcstat2.34
Results
In terms of predictor effect estimates, the log hazard ratios
and standard errors were very similar regardless of
whether Cox models or FPMs were used (Table 3). The log
hazard ratios were fairly similar for full cohort and period
analysis, however the standard errors from the period
analysis approaches were around twice as large due to the
reduction in sample size. Overfitting was minimial due to
the large number of events relative to the number of pre-
dictor parameters, highlighted by a uniform shrinkage fac-
tor35 for the full cohort model of 0.999.
Similar marginal survival predictions were produced re-
gardless of whether Cox or FPMs were used when predict-
ing for patients diagnosed in 2006 (Figure 2). The marginal
survival predictions for temporal recalibration and period
analysis were very similar and consistently provided more
well-calibrated estimates than the standard full cohort
Table 2. Baseline characteristics of the 48 861 participants in
the development dataset once participants with missing pre-
dictor values were removed. Mean (SD) is presented for con-
tinuous variables and n (%) for categorical variables
Variable Mean (SD) or n (%)
Age 70.1 (13.0)
Sex
Male 23 674 (48.5%)
Female 25 187 (51.5%)
Race
White 42 296 (86.6%)
Black 6565 (13.4%)
Stage at diagnosis
Stage 1 18 469 (37.8%)
Stage 2 21 529 (44.1%)
Stage 3 8863 (18.1%)
Grade of tumour at diagnosis
Grade 1 5496 (11.2%)
Grade 2 32 992 (67.5%)
Grade 3 9871 (20.2%)
Grade 4 502 (1.0%)
Table 3. Comparison of the sample size, number of events, log hazard ratios (HR) and standard errors (s.e.) of the log hazard ra-
tios for the categorical predictors in each model
Flexible parametric survival model Cox proportional hazards model
Full cohort Period analysis Full cohort Period analysis
Sample size 48 861 33 197 48 861 33 197
Number of events 12 040 2900 12 040 2900
Predictor effects: log HR (s.e. of log HR) Female 0.05 (0.018) 0.10 (0.038) 0.05 (0.018) 0.10 (0.038)
Black 0.24 (0.025) 0.27 (0.051) 0.24 (0.025) 0.27 (0.051)
Stage 2 1.15 (0.031) 1.18 (0.060) 1.15 (0.031) 1.18 (0.060)
Stage 3 2.98 (0.031) 2.92 (0.062) 2.96 (0.031) 2.90 (0.062)
Grade 2 0.22 (0.039) 0.09 (0.073) 0.22 (0.039) 0.10 (0.073)
Grade 3 0.68 (0.041) 0.55 (0.078) 0.67 (0.041) 0.54 (0.078)
Grade 4 0.81 (0.088) 0.78 (0.146) 0.79 (0.088) 0.75 (0.146)
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model. The survival probability is under-estimated for all
risk groups in the full cohort analysis models, and in 9 of
the 10 groups the predictions are the furthest from the
reference line. However, using temporal recalibration, all
the predicted survival estimates increase and agree more
closely with the Kaplan–Meier estimates. Although the
marginal survival predictions from the temporal recalibra-
tion and period analysis models are very similar, small dif-
ferences in predicted survival can be seen for the highest
risk groups. Including time-dependent effects for age and
stage in the FPM improves the calibration in the third high-
est risk group, however there is very little difference in the
marginal survival estimates, see Supplementary File 3,
available as Supplementary data at IJE online.
A comparison of the model performance in terms of cal-
ibration and concordance of survival predictions is dis-
played in Table 4. Calibration improves by 0.02 by
performing temporal recalibration which is large at the
population level and improves the net benefit of the
model.36 In other scenarios, the difference may be greater
if there have been more substantial changes in baseline sur-
vival over calendar time. As the predictor effects for the
temporal recalibration models are constrained to be the
Figure 2 External validation of the models to assess the calibration of survival predictions for new patients (diagnosed in 2006 with follow-up data un-
til 2015). Top: comparison of marginal observed (Kaplan–Meier) and predicted survival from each model. Note: The predictions from the temporal
recalibration and period analysis models overlay almost exactly. Bottom: 10-year calibration plots comparing the observed and predicted cancer-spe-
cific survival probabilities from each model.
Table 4. Comparison of model performance in the validation
dataset. The difference in observed and predicted marginal
survival at 10 years after diagnosis [Sobs(10) – Sexp(10)], the
ratio of expected to observed risk at 10 years after diagnosis
(E/O) and Harrell’s c-index




Full cohort: FPM 0.056 1.169 0.788
Full cohort: Cox 0.051 1.155 0.788
Temporal recalibration: FPM 0.031 1.094 0.788
Temporal recalibration: Cox 0.031 1.095 0.788
Period analysis: FPM 0.032 1.098 0.788
Period analysis: Cox 0.033 1.101 0.788
a Sobs(10), Kaplan–Meier estimate at 10 years after diagnosis; Sexp(10),
10 year marginal survival prediction from the model.






/ije/article-abstract/doi/10.1093/ije/dyaa030/5815624 by guest on 20 April 2020
same as those from the full cohort model, Harrell’s c-index
will always be the same for these models. In this example,
the predictor effects for the period analysis models were
also very similar and therefore Harrell’s c-index is the
same to three decimal places.
Updating Prognostic Models
Temporal recalibration can also be used to produce up-to-
date survival estimates when new data become available
by simply re-estimating the baseline without the need for
repeating the model-building process or re-estimating the
predictor effects. This is akin to previous work by Riley
et al.,37 Schuetz et al.38 and Steyerberg26 that show how
recalibrating the baseline hazard in new (local) settings can
be important. To illustrate this, prognostic models were fit-
ted using FPMs with data from 1986–95, and data from
1996–2005 was used to update these models. As stage was
only available from 1995 onwards, only age, sex, race and
grade were included as predictors, and for simplicity PHs
was assumed. Table 5 defines the models M1-M6 that
were compared in this analysis.
To illustrate the difference in survival predictions for
these models, 10-year survival was estimated for patients
diagnosed in 2006 and compared with the Kaplan–Meier
estimates for these patients, see Figure 3.
Using the original model (M1) resulted in a difference
between the observed and predicted survival of 0.12,
which was reduced to 0.08 by using a longer timespan
(M2) and 0.05 by using a more recent cohort (M3).
Temporal recalibration models (M4 and M5) and the pe-
riod analysis model (M6) produced the closest estimates
which differed by <0.02. Performing temporal recalibra-
tion improves the calibration of the full cohort models by
at least 0.03 and a larger improvement of >0.10 is ob-
served when recalibrating the original full cohort model.
Despite different models being temporally recalibrated, the
predictions overlaid exactly. This demonstrates that
Table 5. Comparison of the data used to estimate the predictor effects and baseline of each flexible parametric survival model
Model Description Data for predictor effects Data for baseline
M1 Original full cohort model 1986–95 1986–95
M2 Full cohort model with all available data 1986–2005 1986–2005
M3 Full cohort model with most recent data 1996–2005 1996–2005
M4 Temporal recalibration of M1 1986–95 Period window 2004–05
M5 Temporal recalibration of M3 1996–2005 Period window 2004–05
M6 Period analysis Period window 2004–05 Period window 2004–05
Figure 3 Comparison of marginal observed (Kaplan–Meier curve) and predicted survival from the original and updated models. Note: The predictions
from the temporal recalibration and period analysis models overlay almost exactly.
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temporal recalibration is appropriate in this example since
the predictor effects do not greatly change over time and
therefore it is only necessary to re-estimate the baseline.
Discussion
Often there are large underlying improvements in survival
over the follow-up available in a model development data-
set, which presents a challenge for subsequently making
predictions for newly diagnosed patients. We have shown
that survival predictions from prognostic models devel-
oped using a standard full cohort approach underestimate
survival of recently diagnosed patients. However, more up-
to-date, and thus accurate, survival predictions can be pro-
duced by developing prognostic models using temporal
recalibration, where the baseline hazard is recalibrated in a
subset of most recent data. This idea is similar to the ap-
proach of period analysis, but has the additional benefit of
more precisely estimating predictor effects as it uses all the
data to estimate the prognostic index.
Unlike period analysis, it is possible to directly apply
temporal recalibration to a range of existing prognostic
models (i.e. Cox PH models, FPMs with time-dependent
effects) to update the survival predictions without the need
of repeating the model-building process or re-estimating
predictor effects. No additional data are required, only a
period analysis sample of the most recent data is needed to
re-estimate the baseline and produce more up-to-date pre-
dictions which better reflect the survival of those currently
being diagnosed. We have also shown the importance of
regularly updating prognostic models when new data be-
come available and how this can easily be achieved using
temporal recalibration.
We have used SEER public use data for colon cancer
patients, with a range of predictors in order to illustrate
the approach. For cancer sites and settings with smaller
improvements over calendar time, the predicted survival
estimates from a standard and temporally recalibrated ap-
proach would differ less. However, the approach would
still be valid in this case. In this example we only showed
complete case analysis, however, temporal recalibration
could be performed on imputed datasets and the survival
predictions from the models could be combined using
Rubin’s rules.39,40 Example code for fitting these models is
included in Supplementary File 2, available as
Supplementary data at IJE online.
Temporal recalibration assumes that the predictor
effects are the same in the recent data as in the full cohort
and therefore do not change as a function of diagnosis
date. This is in contrast to period analysis which updates
both the baseline and the prognostic index. Therefore, the
parameter estimates from the full cohort and period analy-
sis models can be informally compared to verify that this
assumption is plausible. Further, careful consideration
should be given to the consistency of predictor’s values
over time, but this is an issue generally and not specific to
the approach we outline here.
Temporal recalibration is a similar concept to model
updating,41 in which the calibration of predictions from a
previously developed prognostic model are externally vali-
dated using new data obtained from a more recent time
point. In that setting, if the model consistently under or
over predicts survival, it is recalibrated; typically predictor
effects are kept fixed (i.e. as originally estimated), but the
baseline is updated. The difference with temporal recali-
bration is that the period analysis sample (used for the
recalibration) is not a separate dataset and has already
been included in the full cohort model to estimate predictor
effects.
An alternative to temporal recalibration and period
analysis would be to model the year of diagnosis directly
and then predict survival using the most recent year in-
cluded in the model. This approach would make develop-
ing and updating existing prognostic models more
challenging as it would require the year of diagnosis to be
modelled appropriately, which may include time-depen-
dent effects and non-linear terms. This method would also
rely more heavily on extrapolation of effects when produc-
ing long-term survival predictions for the most recent cal-
endar year. However, with temporal recalibration the
long-term hazards are estimated directly from those in-
cluded in the period window. With both temporal recali-
bration and modelling the year of diagnosis it may be
necessary to consider interactions between predictor effects
and year of diagnosis.42
Many existing prognostic models use the standard full
cohort approach. We have illustrated that using temporal
recalibration could update these survival predictions and
be a more accurate reflection of the prognosis of patients
who are currently being diagnosed.
Supplementary data
Supplementary data are available at IJE online.
Funding
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